Reports
Sale
Ischemic Stroke Market Size, Share, Trends, Growth, Analysis: By Indication Type: Large Artery Thrombosis (LAT), Cardioembolic Stroke, Lacunar Stroke, Cryptogenic Stroke; By Diagnosis Type: Imaging Techniques (MRI, CT Scans, and Angiography), Others; By Treatment Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Ischemic Stroke Market Outlook
The ischemic stroke market size is expected to grow at a CAGR of 5.2% during the forecast period of 2024-2032, driven by the rising prevalence of ischemic stroke risk factors such as hypertension, diabetes, obesity, and sedentary lifestyle across the 8 major markets.
Ischemic Stroke Market Overview
Ischemic stroke occurs due to blockage in the arteries that supplies blood to the brain. This type of stroke accounts for 87% of all strokes and causes damage to the brain cells. A recent study estimated the global age-standardized incidence rate of ischemic stroke is expected to increase to 89.32 per 100,000 individuals by 2030, with the projections indicating a higher occurrence in women than men. This rising incidence of the condition is anticipated to drive the ischemic stroke market growth in the near future.
In August 2023 , Enspire DBS Therapy, Inc., secured USD 17.6 million in Series B funding led by Cleveland Clinic Innovations to support the development of its deep brain stimulation (DBS) and rehabilitation therapy for stroke patients. The funds will be primarily utilized for the clinical trial RESTORE, which aims to investigate DBS and rehab therapy’s efficacy in treating chronic upper extremity impairment due to stroke and generate sufficient data for market approval. A previous trial known as EDEN (Electrical Stimulation of the Dentate Nucleus for Upper Extremity Hemiparesis Due to Ischemic Stroke) showed positive results that prompted the Series B raise. Such investments in innovative neuro-stimulation solutions address a specific clinical need and are expected to fuel the ischemic stroke market demand in the forecast period.
The market is also driven by the growing preference for non-invasive procedures to treat and manage ischemic stroke. Moreover, the rise in public health campaigns and heightened patient awareness will fuel market growth.
Ischemic Stroke Market Trends
| Key Trend | Impact |
| Increased Focus on Acute Stroke Management | Increased impetus on the acute management of ischemic stroke has resulted in significant advancements, particularly in thrombolytic therapies and mechanical thrombectomy procedures. These treatments aim to quickly restore blood flow to the brain and minimize neurological damage. |
| Growth in Minimally Invasive Procedures | There is a trend towards adopting minimally invasive procedures for the treatment of ischemic stroke. These procedures reduce recovery times and lower the risk of complications compared to traditional surgery. |
| Advancements in Diagnostic Imaging | Improved diagnostic imaging technologies, such as MRI and CT perfusion scans, are enhancing the accuracy of ischemic stroke diagnosis. |
| Development of Neuroprotective Agents | Research and development efforts are increasingly focused on neuroprotective agents that can protect brain cells from ischemic damage during stroke. |
Ischemic Stroke Market Segmentation
Market Breakup by Indication Type
- Large Artery Thrombosis (LAT)
- Cardioembolic Stroke
- Lacunar Stroke
- Cryptogenic Stroke
The market is segmented by indication type into large artery thrombosis (LAT), cardioembolic stroke, lacunar stroke, and cryptogenic stroke. LAT involves major artery blockage whereas cardioembolic strokes are caused by clots originating in the heart.
Market Breakup by Diagnosis Type
- Imaging Techniques (MRI, CT Scans, and Angiography)
- Blood Tests
- Electrocardiography (ECG/EKG)
The market segmentation by diagnosis type for ischemic stroke comprises imaging techniques (MRI, CT scans, and angiography) to visualize brain structures and blood vessels, blood tests for biomarker analysis, and electrocardiography (ECG/EKG) to detect heart abnormalities.
Market Breakup by Treatment Type
- Thrombolytic Therapy
- Endovascular Procedures
- Anticoagulants & Antiplatelet Drugs
- Neuroprotective Agents
- Rehabilitation Therapies
- Surgical Interventions
By treatment type, the ischemic stroke market share includes thrombolytic therapy, endovascular procedures, anticoagulants and antiplatelet drugs, neuroprotective agents, rehabilitation therapies, along with surgical interventions. Thrombolytic therapy is used to dissolve clots and endovascular procedures are carried out for clot removal. Anticoagulants and antiplatelet drugs help to prevent clot formation.
Market Breakup by End User
- Hospitals and Clinics
- Ambulatory Surgical Centres (ASCs)
- Rehabilitation Centres
End users of the market are hospitals and clinics, ambulatory surgical centers (ASCs), and rehabilitation centers.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- China
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China. The United States dominates the market share, which can be attributed to a well-developed research infrastructure, which further boosts the treatment landscape. Asia Pacific is poised to witness significant growth, owing to rising investments from public and private institutions, aimed at improving the healthcare infrastructure.
Ischemic Stroke Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Medtronic plc
- Genentech, Inc.
- GE Healthcare
- Covidien plc
- Cordis Corporation
- Boston Scientific Corporation
- Boehringer Ingelheim
- Bayer AG
- Abbott Laboratories
- Johnson & Johnson
- Swiss Pharma Pvt. Ltd.
- Bristol Myers Squibb
- Pfizer
- Eli Lilly and Company
- GlaxoSmithKline
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Diagnosis Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Ischemic Stroke Market Report
- How has the ischemic stroke market performed so far and how is it expected it perform in coming years?
- What are the major market trends influencing the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is expected to experience rapid growth during the forecast period?
- How does the prevalence and incidence of ischemic stroke affect the market landscape?
- How does the rise in the geriatric population impact the ischemic stroke market value?
- What treatment type of ischemic stroke will dominate the market share?
- Which diagnostic method is expected to have a high market value in the coming years?
- Which indication type will cover a significant portion of the market segment?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the factors driving regional disparities in ischemic stroke treatment and outcomes?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ischemic Stroke Market Overview – 8 Major Markets
3.1 Ischemic Stroke Market Historical Value (2017-2023)
3.2 Ischemic Stroke Market Forecast Value (2024-2032)
4 Ischemic Stroke Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Therapy Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Therapy Success Rate
6 Ischemic Stroke Epidemiology Analysis – 8 Major Markets
6.1 Epidemiology Overview (2017-2032)
6.2 8MM Epidemiology Scenario Overview (2017-2032)
6.3 United States Ischemic Stroke Epidemiology Forecast (2017-2032)
6.4 EU-4 and United Kingdom Ischemic Stroke Epidemiology Forecast (2017-2032)
6.4.1 Germany Ischemic Stroke Epidemiology Forecast (2017-2032)
6.4.2 France Ischemic Stroke Epidemiology Forecast (2017-2032)
6.4.3 Italy Ischemic Stroke Epidemiology Forecast (2017-2032)
6.4.4 Spain Ischemic Stroke Epidemiology Forecast (2017-2032)
6.4.5 United Kingdom Ischemic Stroke Epidemiology Forecast (2017-2032)
6.5 Japan Ischemic Stroke Epidemiology Forecast (2017-2032)
6.6 China Ischemic Stroke Epidemiology Forecast (2017-2032)
7 Ischemic Stroke Market Landscape- 8 Major Markets
7.1 Ischemic Stroke Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ischemic Stroke Product Landscape
7.2.1 Analysis by Indication Type
7.2.2 Analysis by Diagnosis Type
8 Ischemic Stroke Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ischemic Stroke Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ischemic Stroke Market Segmentation (2017-2032) - 8 Major Markets
11.1 Ischemic Stroke Market (2017-2032) by Indication Type
11.1.1 Market Overview
11.1.2 Large Artery Thrombosis (LAT)
11.1.3 Cardioembolic Stroke
11.1.4 Lacunar Stroke
11.1.5 Cryptogenic Stroke
11.2 Ischemic Stroke Market (2017-2032) by Diagnosis Type
11.2.1 Market Overview
11.2.2 Imaging Techniques (MRI, CT Scans, and Angiography)
11.2.3 Blood Tests
11.2.4 Electrocardiography (ECG/EKG)
11.3 Ischemic Stroke Market (2017-2032) by Treatment Type
11.3.1 Market Overview
11.3.2 Thrombolytic Therapy
11.3.3 Endovascular Procedures
11.3.4 Anticoagulants & Antiplatelet Drugs
11.3.5 Neuroprotective Agents
11.3.6 Rehabilitation Therapies
11.3.7 Surgical Interventions
11.4 Ischemic Stroke Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals and Clinics
11.4.3 Ambulatory Surgical Centres (ASCs)
11.4.4 Rehabilitation Centres
11.5 Ischemic Stroke Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 China
12 United States Ischemic Stroke Market
12.1 United States Ischemic Stroke Market Historical Value (2017-2023)
12.2 United States Ischemic Stroke Market Forecast Value (2024-2032)
12.3 United States Ischemic Stroke Market (2017-2032) by Indication Type
12.3.1 Market Overview
12.3.2 Large Artery Thrombosis (LAT)
12.3.3 Cardioembolic Stroke
12.3.4 Lacunar Stroke
12.3.5 Cryptogenic Stroke
12.4 United States Ischemic Stroke Market (2017-2032) by Diagnosis Type
12.4.1 Market Overview
12.4.2 Imaging Techniques (MRI, CT Scans, and Angiography)
12.4.3 Blood Tests
12.4.4 Electrocardiography (ECG/EKG)
13 EU-4 and United Kingdom Ischemic Stroke Market
13.1 EU-4 and United Kingdom Ischemic Stroke Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Ischemic Stroke Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Ischemic Stroke Market (2017-2032) by Indication Type
13.3.1 Market Overview
13.3.2 Large Artery Thrombosis (LAT)
13.3.3 Cardioembolic Stroke
13.3.4 Lacunar Stroke
13.3.5 Cryptogenic Stroke
13.4 EU-4 and United Kingdom Ischemic Stroke Market (2017-2032) by Diagnosis Type
13.4.1 Market Overview
13.4.2 Imaging Techniques (MRI, CT Scans, and Angiography)
13.4.3 Blood Tests
13.4.4 Electrocardiography (ECG/EKG)
14 Japan Ischemic Stroke Market
14.1 Japan Ischemic Stroke Market Historical Value (2017-2023)
14.2 Japan Ischemic Stroke Market Forecast Value (2024-2032)
14.3 Japan Ischemic Stroke Market (2017-2032) by Indication Type
14.3.1 Market Overview
14.3.2 Large Artery Thrombosis (LAT)
14.3.3 Cardioembolic Stroke
14.3.4 Lacunar Stroke
14.3.5 Cryptogenic Stroke
14.4 Japan Ischemic Stroke Market (2017-2032) by Diagnosis Type
14.4.1 Market Overview
14.4.2 Imaging Techniques (MRI, CT Scans, and Angiography)
14.4.3 Blood Tests
14.4.4 Electrocardiography (ECG/EKG)
15 China Ischemic Stroke Market
15.1 China Ischemic Stroke Market Historical Value (2017-2023)
15.2 China Ischemic Stroke Market Forecast Value (2024-2032)
15.3 China Ischemic Stroke Market (2017-2032) by Indication Type
15.3.1 Market Overview
15.3.2 Large Artery Thrombosis (LAT)
15.3.3 Cardioembolic Stroke
15.3.4 Lacunar Stroke
15.3.5 Cryptogenic Stroke
15.4 China Ischemic Stroke Market (2017-2032) by Diagnosis Type
15.4.1 Market Overview
15.4.2 Imaging Techniques (MRI, CT Scans, and Angiography)
15.4.3 Blood Tests
15.4.4 Electrocardiography (ECG/EKG)
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Medtronic plc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisition
22.1.5 Certifications
22.2 Genentech, Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 GE Healthcare
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Covidien plc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Cordis Corporation
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Boston Scientific Corporation
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Boehringer Ingelheim
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Bayer AG
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Abbott Laboratories
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Johnson & Johnson
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Swiss Pharma Pvt. Ltd.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Bristol Myers Squibb
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 Pfizer
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Eli Lilly and Company
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 GlaxoSmithKline
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
23 Ischemic Stroke Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032, driven by the rising prevalence of ischemic stroke risk factors such as hypertension, diabetes, obesity, and sedentary lifestyle across the 8 major markets.
The market demand is driven by the growing preference for minimally invasive procedures for the treatment of ischemic stroke, along with advancements in diagnostic imaging.
One of the significant trends in the market is the rising investments in innovative therapies to treat ischemic stroke. In August 2023 , Enspire DBS Therapy, Inc. secured USD 17.6 million to support the development of its deep brain stimulation (DBS) and rehabilitation therapy for stroke patients.
Based on the indication type, the market is segmented into large artery thrombosis (LAT), cardioembolic stroke, lacunar stroke, and cryptogenic stroke.
Based on the treatment type, the market is segmented into thrombolytic therapy, endovascular procedures, anticoagulant and antiplatelet drugs, neuroprotective agents, rehabilitation therapies, and surgical interventions.
Major end users of the market are hospitals and clinics, ambulatory surgical centers (ASCs), and rehabilitation centers.
The market segmentation by diagnosis type for ischemic stroke comprises imaging techniques (MRI, CT scans, and angiography), blood tests, and electrocardiography (ECG/EKG).
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China.
Key players involved in the market are Medtronic plc, Genentech, Inc., GE Healthcare, Covidien plc, Cordis Corporation, Boston Scientific Corporation, Boehringer Ingelheim, Bayer AG, Abbott Laboratories, Johnson & Johnson, Swiss Pharma Pvt. Ltd., Bristol Myers Squibb, Pfizer, Eli Lilly and Company, and GlaxoSmithKline.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER